Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04964544 · ClinicalTrials.gov registry record · Phase 3
Technology-Assisted Cholesterol Trial in Consumers (TACTiC)
A Phase 3 study of High Cholesterol, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,196
- Enrollment target
- 1
- Study location
NCT04964544 is a Phase 3 study of High Cholesterol that has completed, run by AstraZeneca. The registered enrollment target is 1,196 participants, above the 168-participant average among 4 other High Cholesterol trials with a reported enrollment target (612% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04964544, a Phase 3 study of High Cholesterol, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,196 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this AUS is to evaluate the extent to which participants can safely and effectively self-select, purchase, and use Crestor OTC 5 mg for a 6-month period according to the label.
Conditions Studied
Interventions
- COMBINATION_PRODUCT 5 mg rosuvastatin calcium with a Web App (combination product)
Study Locations (1)
Indiana
- Research Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,196 participants |
| Start Date | 2021-07-08 |
| Est. Completion | 2023-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04964544
The ClinicalTrials.gov registry entry for NCT04964544 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,196 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 168-participant average among 4 other High Cholesterol trials with a reported enrollment target (612% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High Cholesterol appearing as the primary indexed condition, and to 1 intervention - of which 5 mg rosuvastatin calcium with a Web App (combination product) is the first listed.
NCT04964544 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT04964544 about?
NCT04964544 is a clinical study titled "Technology-Assisted Cholesterol Trial in Consumers (TACTiC)". The purpose of this AUS is to evaluate the extent to which participants can safely and effectively self-select, purchase, and use Crestor OTC 5 mg for a 6-month period according to the label.
What is the current status of trial NCT04964544?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,196 participants. The study started on 2021-07-08. Estimated completion is 2023-03-01.
What conditions does trial NCT04964544 study?
This clinical trial studies the following conditions: High Cholesterol.
What interventions are being tested in trial NCT04964544?
The interventions under investigation include: 5 mg rosuvastatin calcium with a Web App (combination product) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04964544?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04964544 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Cholesterol
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.